Brett Matthew Hall - 15 Sep 2025 Form 4 Insider Report for Immuneering Corp (IMRX)

Role: CHIEF SCIENTIFIC OFFICER
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Brett Matthew Hall
Issuer symbol: IMRX
Transactions as of: 15 Sep 2025
Transactions value $: $21,249
Form type: 4
Date filed: 17 Sep 2025, 16:30
Previous filing: 24 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	245 MAIN STREET, SECOND FLOOR, CAMBRIDGE	/s/ Michael D. Bookman, Attorney-in-Fact for Brett Matthew Hall	2025-09-17	0001870437

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMRX	Class A Common Stock	Award	$21.2K	+14.9K	+4.14%	$1.43	374K	15 Sep 2025	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 16, 2025 through September 15, 2025. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
F2	The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2025.
F3	In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of the relevant Offering Period.